CTOs on the Move

Compass Health

www.compasshealth.org

 
Compass Health`s mission is to champion the quest for well-being throughout our communities, and advance behavioral health in Snohomish, Skagit, Island, San Juan, and Whatcom counties. Compass Health was first established as Parkland Lutheran Children’s Home in 1901, caring for orphaned children in Western Washington.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Compass Health raised $17M on 07/20/2018

Similar Companies

Acucela

Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.

Alliant Healthcare Products

Alliant Healthcare Products is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AdminaHealth

AdminaHealth is a cloud-based solution provider that develops technology and financial solutions for the benefit and insurance marketplace. The company provides unique operational, reporting and financial solutions to brokers, TPAs, captive managers and the employers and associations they serve. Our goal is to continue to develop solutions that will lower benefit costs while maintaining or improving benefit levels.

TrestleTree

TrestleTree is a Springdale, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.